vs
Side-by-side financial comparison of SCYNEXIS INC (SCYX) and Voyager Technologies, Inc. (VOYG). Click either name above to swap in a different company.
Voyager Technologies, Inc. is the larger business by last-quarter revenue ($35.2M vs $18.6M, roughly 1.9× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs -130.4%, a 196.1% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 2.1%).
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
SCYX vs VOYG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $35.2M |
| Net Profit | $12.3M | $-45.9M |
| Gross Margin | — | -4.4% |
| Operating Margin | 56.3% | — |
| Net Margin | 65.7% | -130.4% |
| Revenue YoY | 1808.5% | 2.1% |
| Net Profit YoY | 376.5% | -64.5% |
| EPS (diluted) | $0.25 | $-0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $35.2M | ||
| Q4 25 | $18.6M | $46.7M | ||
| Q3 25 | $334.0K | $39.6M | ||
| Q2 25 | $1.4M | $45.7M | ||
| Q1 25 | $257.0K | — | ||
| Q4 24 | $977.0K | — | ||
| Q3 24 | $660.0K | — | ||
| Q2 24 | $736.0K | — |
| Q1 26 | — | $-45.9M | ||
| Q4 25 | $12.3M | $-33.0M | ||
| Q3 25 | $-8.6M | $-16.3M | ||
| Q2 25 | $-6.9M | $-31.4M | ||
| Q1 25 | $-5.4M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-2.8M | — | ||
| Q2 24 | $-14.5M | — |
| Q1 26 | — | -4.4% | ||
| Q4 25 | — | 21.4% | ||
| Q3 25 | — | 15.4% | ||
| Q2 25 | — | 18.0% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 56.3% | — | ||
| Q3 25 | -2516.5% | -60.7% | ||
| Q2 25 | -701.0% | -52.8% | ||
| Q1 25 | -3350.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1563.6% | — | ||
| Q2 24 | -1255.0% | — |
| Q1 26 | — | -130.4% | ||
| Q4 25 | 65.7% | -70.7% | ||
| Q3 25 | -2572.2% | -41.1% | ||
| Q2 25 | -504.8% | -68.7% | ||
| Q1 25 | -2097.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -425.5% | — | ||
| Q2 24 | -1964.4% | — |
| Q1 26 | — | $-0.75 | ||
| Q4 25 | $0.25 | $-0.52 | ||
| Q3 25 | $-0.17 | $-0.28 | ||
| Q2 25 | $-0.14 | $-1.23 | ||
| Q1 25 | $-0.11 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.06 | — | ||
| Q2 24 | $-0.30 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.0M | $429.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $49.4M | $404.5M |
| Total Assets | $59.0M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $429.4M | ||
| Q4 25 | $40.0M | $491.3M | ||
| Q3 25 | $37.9M | $413.3M | ||
| Q2 25 | $44.8M | $468.9M | ||
| Q1 25 | $40.6M | — | ||
| Q4 24 | $59.3M | — | ||
| Q3 24 | $68.8M | — | ||
| Q2 24 | $73.0M | — |
| Q1 26 | — | $404.5M | ||
| Q4 25 | $49.4M | — | ||
| Q3 25 | $36.4M | $590.9M | ||
| Q2 25 | $44.5M | $554.7M | ||
| Q1 25 | $50.5M | — | ||
| Q4 24 | $55.1M | — | ||
| Q3 24 | $58.5M | — | ||
| Q2 24 | $60.4M | — |
| Q1 26 | — | $1.0B | ||
| Q4 25 | $59.0M | — | ||
| Q3 25 | $51.1M | $727.8M | ||
| Q2 25 | $60.7M | $685.3M | ||
| Q1 25 | $67.9M | — | ||
| Q4 24 | $90.6M | — | ||
| Q3 24 | $99.0M | — | ||
| Q2 24 | $107.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.4M | $-39.7M |
| Free Cash FlowOCF − Capex | — | $-66.8M |
| FCF MarginFCF / Revenue | — | -189.5% |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.50× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-263.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-39.7M | ||
| Q4 25 | $18.4M | $-60.9M | ||
| Q3 25 | $-8.7M | $-15.1M | ||
| Q2 25 | $-7.5M | $-30.9M | ||
| Q1 25 | $-7.5M | — | ||
| Q4 24 | $-24.0M | — | ||
| Q3 24 | $765.0K | — | ||
| Q2 24 | $-10.9M | — |
| Q1 26 | — | $-66.8M | ||
| Q4 25 | — | $-54.5M | ||
| Q3 25 | — | $-53.8M | ||
| Q2 25 | — | $-88.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | -189.5% | ||
| Q4 25 | — | -116.9% | ||
| Q3 25 | — | -135.8% | ||
| Q2 25 | — | -194.4% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 97.8% | ||
| Q2 25 | — | 126.7% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.50× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
VOYG
Segment breakdown not available.
